At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
In Brief
A clinical study evaluating Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download and Medication intervention for Heart Failure NYHA Class II and Heart Failure NYHA Class III. Completed, enrolled 826 participants across 53 sites.
Detailed Summary
The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study. The purpose of the study is to demonstrate the safety and efficacy of a patient management pathway that utilizes an integrated device diagnostic-based risk stratification algorithm to guide patient care in subjects with NYHA class II and III heart failure, and to demonstrate the safety of the Reveal LINQ™ system and procedure in the study population.
Study Details
Timeline
Interventions
Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
Risk status guided medication intervention.